Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs AMMONIUM CHLORIDE 2.14%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Ammonium chloride is an acidifying agent. It dissociates into ammonium and chloride ions. The ammonium ion is metabolized in the liver to urea and hydrogen ions, leading to metabolic acidosis. This reduces blood p H and increases renal excretion of alkaline urine.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Treatment of metabolic alkalosis,Urinary acidification to enhance excretion of weak bases (e.g., amphetamines, quinidine) or to promote dissolution of calcium phosphate stones
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
For metabolic alkalosis: 1.5 to 3 g (approximately 280 to 560 m Eq) intravenously over 4 to 6 hours; adjust based on serum chloride and p H.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
4-6 hours; prolonged in renal impairment (up to 12-15 hours).
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Converted to urea and hydrogen ions in the liver via the urea cycle.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal: >99% as ammonium ion and chloride; minimal biliary/fecal elimination.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Negligible (<1%); not significantly bound to plasma proteins.
4-6 L/kg; large Vd indicates extensive tissue distribution
0.3-0.5 L/kg; distributes primarily in extracellular fluid; clinical meaning: low Vd reflects limited tissue penetration.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral: 100% (fully absorbed); IV: 100%; topical: non-systemic.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 50% and monitor serum electrolytes. For GFR >60 m L/min: no adjustment.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
No specific Child-Pugh based adjustment; use caution in severe hepatic impairment due to risk of ammonia toxicity.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Neonates and children: 1-2 m Eq/kg intravenously per dose, infused over 2-4 hours; maximum 100 m Eq per dose. Titrate based on serum chloride and acid-base status.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Start at lower end of adult dosing (e.g., 1.5 g intravenously) due to age-related decreased renal function; monitor electrolytes and renal function closely.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Avoid in patients with impaired renal or hepatic function; may cause hyperammonemia and hepatic coma.,Use with caution in patients with cardiac failure or pulmonary edema due to risk of fluid overload.,Monitor serum chloride, bicarbonate, and p H levels during therapy.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Severe hepatic insufficiency,Severe renal impairment,Hyperammonemia,Uremia,Ammonium toxicity
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
No significant food interactions known. However, a diet low in chloride may reduce efficacy. Avoid excessive intake of alkalinizing foods (e.g., citrus fruits, vegetables) that may counteract the acidifying effect.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Ammonium chloride is not known to be teratogenic in humans. No structural anomalies have been reported with first trimester exposure. In second and third trimesters, maternal acidosis from excessive dosing could potentially affect fetal acid-base balance, but no specific fetal risks are documented. Overall, classified as FDA Pregnancy Category C.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Excretion into breast milk is unknown. M/P ratio not available. Caution advised due to potential for neonatal acidosis if maternal doses are high. Short-term use is likely compatible with breastfeeding.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No specific dosing adjustments required in pregnancy. However, due to pregnancy-associated hyperventilation and renal changes, monitor acid-base status. Initiate at low doses and titrate based on serum chloride and bicarbonate levels.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Ammonium chloride 2.14% is a systemic acidifying agent used to treat metabolic alkalosis. Monitor serum electrolytes (especially chloride and bicarbonate) and arterial blood gases closely. Avoid in patients with severe hepatic or renal impairment, as ammonium ions can precipitate hepatic encephalopathy or worsen acidosis. Infuse slowly to prevent hemolysis. Use with caution in patients with respiratory acidosis.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
This medication is used to treat low acid levels in the blood.,Your healthcare provider will monitor your blood tests regularly while on this medicine.,Report any signs of allergic reaction (rash, itching, swelling) or symptoms of acidosis (confusion, rapid breathing) immediately.,Avoid taking other medications or supplements without consulting your doctor, as they may interfere with this treatment.,Do not stop this medication abruptly without medical advice.
No interactions on record
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs AMMONIUM CHLORIDE 2.14%, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. AMMONIUM CHLORIDE 2.14% is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent. It dissociates into ammonium and chloride ions. The ammonium ion is metabolized in the liver to urea and hydrogen ions, leading to metabolic acidosis. This reduces blood p H and increases renal excretion of alkaline urine.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and AMMONIUM CHLORIDE 2.14% depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of AMMONIUM CHLORIDE 2.14% is: For metabolic alkalosis: 1.5 to 3 g (approximately 280 to 560 m Eq) intravenously over 4 to 6 hours; adjust based on serum chloride and p H.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and AMMONIUM CHLORIDE 2.14% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. AMMONIUM CHLORIDE 2.14% is classified as Category C. Ammonium chloride is not known to be teratogenic in humans. No structural anomalies have been reported with first trimester exposure. In second and third trimesters, maternal acido. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.